Cecilia Jones - 01 Mar 2026 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Mar 2026, 16:14:52 UTC
Prior SEC filing
02 Jan 2026
Next SEC filing
06 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ William Cook, as attorney-in-fact for Cecilia Jones

Key filing fact

Cecilia Jones filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 03 Mar 2026.

Key facts

  • This page summarizes Cecilia Jones's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
  • 14 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 03 Mar 2026, 16:14.

Change

  • Previous filing in this sequence was filed on 02 Jan 2026.
  • Current net transaction value: -$145,814.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001840056 Primary reporting owner

Jones Cecilia

Relationship
Chief Financial Officer
Address
C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE
Signature
/s/ William Cook, as attorney-in-fact for Cecilia Jones
Signature date
03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AGIO transaction

Common stock

Options Exercise

Transaction value
$0
Shares
+2,000
Change %
+5.3%
Price
$0.000000
Shares after
39,394
Date
02 Mar 2026
Ownership
Direct
AGIO transaction

Common stock

Sale

Transaction value
$17,202
Shares
-594
Change %
-1.5%
Price
$28.96
Shares after
38,800
Date
02 Mar 2026
Ownership
Direct
Footnotes
F1
AGIO transaction

Common stock

Options Exercise

Transaction value
$0
Shares
+5,666
Change %
+15%
Price
$0.000000
Shares after
44,466
Date
02 Mar 2026
Ownership
Direct
AGIO transaction

Common stock

Sale

Transaction value
$48,682
Shares
-1,681
Change %
-3.8%
Price
$28.96
Shares after
42,785
Date
02 Mar 2026
Ownership
Direct
Footnotes
F2
AGIO transaction

Common stock

Options Exercise

Transaction value
$0
Shares
+4,000
Change %
+9.3%
Price
$0.000000
Shares after
46,785
Date
02 Mar 2026
Ownership
Direct
AGIO transaction

Common stock

Sale

Transaction value
$34,376
Shares
-1,187
Change %
-2.5%
Price
$28.96
Shares after
45,598
Date
02 Mar 2026
Ownership
Direct
Footnotes
F3
AGIO transaction

Common stock

Options Exercise

Transaction value
$0
Shares
+5,303
Change %
+12%
Price
$0.000000
Shares after
50,901
Date
02 Mar 2026
Ownership
Direct
AGIO transaction

Common stock

Sale

Transaction value
$45,554
Shares
-1,573
Change %
-3.1%
Price
$28.96
Shares after
49,328
Date
02 Mar 2026
Ownership
Direct
Footnotes
F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGIO transaction Derivative

Restricted stock units

Award

Transaction value
$0
Shares
+14,000
Change %
Price
$0.000000
Shares after
14,000
Date
01 Mar 2026
Ownership
Direct
Underlying class
Common stock
Underlying amount
14,000
Exercise price
Footnotes
F4, F5
AGIO transaction Derivative

Stock options (right to buy)

Award

Transaction value
$0
Shares
+52,000
Change %
Price
$0.000000
Shares after
52,000
Date
01 Mar 2026
Ownership
Direct
Underlying class
Common stock
Underlying amount
52,000
Exercise price
$30.23
Footnotes
F6
AGIO transaction Derivative

Restricted stock units

Options Exercise

Transaction value
$0
Shares
-2,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
02 Mar 2026
Ownership
Direct
Underlying class
Common stock
Underlying amount
2,000
Exercise price
Footnotes
F4, F7
AGIO transaction Derivative

Restricted stock units

Options Exercise

Transaction value
$0
Shares
-5,666
Change %
-50%
Price
$0.000000
Shares after
5,667
Date
02 Mar 2026
Ownership
Direct
Underlying class
Common stock
Underlying amount
5,666
Exercise price
Footnotes
F4, F8
AGIO transaction Derivative

Restricted stock units

Options Exercise

Transaction value
$0
Shares
-4,000
Change %
-33%
Price
$0.000000
Shares after
8,000
Date
02 Mar 2026
Ownership
Direct
Underlying class
Common stock
Underlying amount
4,000
Exercise price
Footnotes
F4, F9
AGIO transaction Derivative

Restricted stock units

Options Exercise

Transaction value
$0
Shares
-5,303
Change %
-33%
Price
$0.000000
Shares after
10,607
Date
02 Mar 2026
Ownership
Direct
Underlying class
Common stock
Underlying amount
5,303
Exercise price
Footnotes
F4, F9
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 9 footnotes

Footnote F1

Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.

Footnote F2

Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024.

Footnote F3

Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025.

Footnote F4

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F5

The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.

Footnote F6

This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Footnote F7

The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.

Footnote F8

The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.

Footnote F9

The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .